Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
(Thomson Reuters ONE) -
Novartis International AG /
Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for
myopic choroidal neovascularization
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Lucentis(®) (ranibizumab) is the first licensed therapy to improve vision in
patients with visual impairment due to choroidal neovascularization
secondary to pathologic myopia
* Pivotal trial shows average visual acuity improvement of up to 14 letters at
one year with a median of only two injections with Lucentis treatment
* Myopic CNV, the growth of abnormal leaky blood vessels in the back of the
eye in high myopia, often causes irreversible deterioration of central
vision
Basel, July 5, 2013 - The European Commission has granted Novartis a new
indication for Lucentis(®) (ranibizumab) to treat patients with visual
impairment due to choroidal neovascularization (CNV) secondary to pathologic
myopia (myopic CNV). This makes Lucentis, specifically designed for the eye and
proven to save sight, the first anti-VEGF therapy licensed for four indications
in the European Union. Pathologic myopia often affects working-age adults and is
a major cause of vision loss worldwide, with 1-3% of the general
population[1],[2]. CNV is the most common vision-threatening complication of
high myopia[3]. In patients with untreated myopic CNV the long-term prognosis is
poor with approximately 90% of affected patients developing severe vision loss
after five years. The resulting visual loss from myopic CNV which usually
affects people younger than 50 years old has a profound effect on productivity,
financial status, career expectations, and quality of life in working-age
individuals.
According to the European label, treatment of myopic CNV starts with a single
injection. Any further injections are based on an individualized regimen.
Retreatment is based on vision and anatomical changes, and monitoring is
required monthly for the first two months and then at least quarterly up to one
year; in the second year monitoring is at the discretion of the treating
physician.
RADIANCE, the Novartis-sponsored clinical trial in patients with myopic CNV,
shows that Lucentis provides rapid and superior improvement in visual acuity
compared with the current licensed standard of care, Visudyne(®) (verteporfin
PDT). There is an average 14-letter visual acuity gain in the first year with a
median of 2 injectionsand over 60% of patients in RADIANCE did not need any
further injections after 6 months[5].
"We are committed to fully understanding medical retina and to serving unmet
patient needs. This fourth indication for our pioneering ophthalmology drug,
Lucentis, shows how far we have come since it was first launched in 2006," said
Tim Wright, Global Head of Development, Novartis Pharmaceuticals. "We expect
that the use of Lucentis will significantly change the treatment of myopic CNV,
as it is the first and only licensed treatment that has been proven to restore
vision in patients with visual impairment due to myopic CNV."
Rapid visual acuity gains were achieved after only a single Lucentis injection
and more than 70% of patients treated with Lucentis in RADIANCE experienced a
reduction in CNV leakage and intraretinal edema, with central retinal thickness
being significantly reduced from as early as month one.
Lucentis has a well-established safety profile and its safety profile in
RADIANCE was consistent with that observed in other studies, as well as in real-
world experience, and no new ocular/non-ocular safety risks were identified.
About Lucentis(®) (ranibizumab)
Lucentis is a humanized therapeutic antibody fragment designed to block all
biologically active forms of vascular endothelial cell growth factor-A (VEGF-A).
Increased levels of VEGF-A are seen in wet AMD and other ocular diseases such as
diabetic macular edema (DME) and retinal vein occlusion (RVO). Lucentis was
specifically designed for the eye, minimizing systemic exposure.
Lucentis is licensed for the treatment of wet AMD in more than 100 countries, in
more than 90 countries for the treatment of visual impairment due to DME and in
90 countries for visual impairment due to macular edema secondary to RVO,
including both branch- and central-RVO. In many countries, including those in
Europe, Lucentis has an individualized treatment regimen with the goal of
maximizing visual outcomes while minimizing under- or over-treating patients.
Lucentis has a well-established safety profile supported by 43 extensive
sponsored clinical studies and real-world experience. Its safety profile has
been well established in a clinical development program that enrolled more than
12,500 patients across indications and there is more than 1.7 million patient-
treatment years of exposure since its launch in the United States in 2006.
Lucentis was developed by Genentech and Novartis. Genentech has the commercial
rights to Lucentis in the United States. Novartis has exclusive rights in the
rest of the world. Lucentis is a registered trademark of Genentech Inc.
Novartis sponsors the eXcellence in Ophthalmology Vision Award (XOVA). XOVA is
an annual award launched in 2010 that provides funding to non-profit initiatives
and projects that will have a positive impact on improving the quality of eye
care and make a significant impact in addressing unmet needs in the fields of
ophthalmology and optometry.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "committed," "expect," "will," or similar expressions, or
by express or implied discussions regarding potential new indications or
labeling for Lucentis or regarding potential future revenues from Lucentis. You
should not place undue reliance on these statements. Such forward-looking
statements reflect the current views of management regarding future events, and
involve known and unknown risks, uncertainties and other factors that may cause
actual results with Lucentis to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee that Lucentis will be approved for any additional indications or
labeling in any market. Nor can there be any guarantee that Lucentis will
achieve any particular levels of revenue in the future. In particular,
management's expectations regarding Lucentis could be affected by, among other
things, unexpected clinical trial results, including unexpected new clinical
data and unexpected additional analysis of existing clinical data; competition
in general; government, industry and general public pricing pressures;
unexpected regulatory actions or delays or government regulation generally; the
company's ability to obtain or maintain patent or other proprietary intellectual
property protection; unexpected manufacturing issues; the impact that the
foregoing factors could have on the values attributed to the Novartis Group's
assets and liabilities as recorded in the Group's consolidated balance sheet,
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 129,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
[1] Silva R et al. Myopic maculopathy: A review. Ophthalmologica
2012;228:197-213.
[2] Shi Y et al. Exome sequencing identifies ZNF644 mutations in high myopia.
PLOS Genet 2011;7: e1002084.
[3] Neelam K et al. Choroidal neovascularization in pathological myopia. Prog
Retin Eye Res 2012;31:495-525.
[4] Yoshida T et al. Myopic choroidal neovascularization: a 10-year follow-up.
Ophthalmology 2003;110:1297-1305.
[5] Bandello F. Twelve-month efficacy and safety of ranibizumab 0.5 mg versus
verteporfin photodynamic therapy in the treatment of visual impairment due to
choroidal neovascularization secondary to pathologic myopia. Association for
Research in Vision and Ophthalmology 2013.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Mark Grossien
Novartis Global Media Relations Novartis Pharmaceuticals Communications
+41 61 324 7999 (direct) +41 61 696 5780 (direct)
+41 79 593 4202 (mobile) +41 79 489 7688 (mobile)
eric.althoff(at)novartis.com mark.grossien(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1714478/569344.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1714478]
Unternehmensinformation / Kurzprofil:
Datum: 05.07.2013 - 07:17 Uhr
Sprache: Deutsch
News-ID 275816
Anzahl Zeichen: 12456
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
